LeMaitre Vascular Signals Strong Earnings Momentum

Lemaitre Vascular ((LMAT)) has held its Q1 earnings call. Read on for the main highlights of the call.

LeMaitre Vascular’s latest earnings call struck a clearly upbeat tone, with management emphasizing broad-based, high-quality growth, record performances across products and regions, and substantial margin expansion. While leaders acknowledged execution and regulatory risks around selected products and geographies, the overarching message was one of accelerating momentum backed by upgraded guidance.

Revenue Growth Driven by Pricing and Direct Sales

Q1 sales rose 11% year over year, with organic growth of 10% powered mainly by an 8% increase in average selling prices and 2% unit growth. Direct sales were particularly strong, growing 12.8% organically when excluding distribution, with 8.4% from price and 4.4% from volume.

Margin Expansion and Profitability Surge

Profitability improved sharply as gross margin reached 72.7% in Q1, up 350 basis points from a year ago thanks to richer pricing, favorable mix and manufacturing efficiencies. Operating income jumped 41% to $17.8 million, lifting the operating margin to 27% from 21%, underscoring strong operating leverage.

EPS Upside and Robust Cash Generation

Earnings power accelerated, with fully diluted EPS climbing 42% to $0.68 on the back of higher margins and disciplined costs. Cash flow from operations increased to $15.1 million versus $9 million last year, leaving LeMaitre with $367 million in cash and securities even after paying $5.7 million in dividends.

Product Categories Deliver Record Performances

Key product lines posted record sales in Q1, highlighting the breadth of demand across the portfolio and supporting the company’s premium pricing strategy. Grafts led with 20% growth, while valvulotomes grew 15% and carotid shunts advanced 11%, all reaching new quarterly highs.

Global Footprint and Sales Force Expansion

All three regions hit record sales, with EMEA up 20%, APAC up 18% and the Americas up 7%, signaling balanced global momentum. LeMaitre continues to expand direct presence and commercial reach, planning a Poland launch in Q4 and growing to 158 reps and 35 regional sales managers, both up year on year.

Artegraft Becomes a Key Growth Engine

Artegraft delivered standout performance, with worldwide sales up 36% and international sales reaching $2.1 million in Q1 alone. Management is targeting a steep ramp, projecting Artegraft sales to jump to $10 million in 2026 from $4 million in 2025, supported by Health Canada approval and a planned second-half 2026 launch.

RestoreFlow Allograft Poised for Wider Adoption

RestoreFlow Allograft growth remained solid at 25% in Q1, and the company is laying groundwork for broader international penetration. German implants are slated to begin in Q2, with Irish approval and warehouse certification expected in the second half, and regulatory filings planned in Australia and additional European markets in 2026.

Guidance Raised on Revenue, Margins and EPS

LeMaitre reaffirmed its 2026 revenue target of $280 million, implying about 12% organic growth, and lifted its gross margin outlook to 72.3% alongside operating income guidance of $79.8 million. Adjusted diluted EPS guidance was raised to $3.00, roughly 26% growth versus 2025, while Q2 is guided to $71.5 million in revenue and a 30% operating margin.

Operational Efficiencies Support Structural Margins

Management highlighted ongoing automation and lean manufacturing initiatives as durable drivers of higher profitability and capacity. Direct labor is expected to fall from 211 employees at the end of 2023 to 175 by the end of 2025, even as device output increases, reinforcing the sustainability of elevated gross margins.

M&A Pipeline Targets Niche Surgical Assets

The company continues to pursue bolt-on acquisitions, reporting two to three term sheets so far this year in its chosen vascular and cardiac surgery niches. Targets typically generate $15 million to $150 million in revenue, and the playbook emphasizes quality products, direct commercial expansion and strong profitability.

Distribution Volatility Weighs on Unit Growth

Despite solid overall sales, unit growth was modest at 2%, reflecting a softer quarter for the distribution business, which tends to be lumpy. This volatility meant distribution contributed less to organic growth than usual, though management framed the impact as timing rather than structural demand weakness.

Patches Segment Lags Broader Portfolio

The patches category was a clear underperformer in Q1, with organic growth of just 2.3% compared with double-digit gains elsewhere. Core product XenoSure grew only 5%, signaling a slowdown that contrasts with the strength in grafts, valvulotomes and shunts and marking an area for potential strategic focus.

Artegraft U.S. Label Limits Near-Term Upside

In the U.S., Artegraft’s current label restricts cannulation to 10 days after implantation, limiting its use in dialysis access and slowing market expansion. The company has filed a pre-submission with regulators for Quick Stick AV access indications, but it estimates the process could take two to five years or more, extending the timeline for full commercialization.

RFA European Rollout Faces Early Hurdles

The rollout of RestoreFlow Allograft in Europe has been slower than expected, with German implants delayed despite approval due to the need for additional qualified inventory. Irish authorization and warehouse audits have also slipped, and management characterized initial European uptake as light, adding execution risk to the growth story.

Short-Term Transitions Pressure Margins

Near-term gross margin guidance of 72.1% for Q2 reflects the cost drag from operational transitions including a new Billerica warehouse and moving RFA processing to Burlington. These changes create temporary margin headwinds and operational complexity, even as management maintains a higher full-year margin outlook.

Rising Opex and Planned Commercial Investments

Operating expenses grew 6% year over year to $30.6 million in Q1, and the company plans to step up commercial spending in the second half as it ramps its sales force. These investments could temper near-term margin expansion, but management argues they are necessary to support sustained top-line growth and pipeline launches.

Geopolitical and Supply Chain Risks Persist

Management flagged that recent instability in the Middle East prevented shipment of about $175,000 of exports at quarter-end, underscoring ongoing geopolitical risk. The company also noted potential future pressures on supply chains and transportation costs, which could intermittently affect revenue timing and profitability.

Guidance Hinges on Stable FX and flawless Execution

LeMaitre’s outlook assumes a constant EUR/USD exchange rate of 1.17 and no dilution from convertible debt, conditions that introduce some sensitivity to external factors. Hitting ambitious targets, such as taking international Artegraft sales from the current run-rate toward $10 million in 2026, will also require timely launches and regulatory wins, highlighting execution risk.

The earnings call painted a picture of a company enjoying strong momentum, with pricing power, margin expansion and cash generation all moving in the right direction. While management was candid about product-specific and geopolitical risks, the upgraded guidance and clear growth levers across Artegraft, RFA and global markets left investors with a generally optimistic outlook on LeMaitre Vascular’s trajectory.